April 13th -15th, 2015 - Theme 9 - Big Data, Mobile Health
Harnessing Big Data to make better, quicker medical decisions is a logical development. However, this demands a delicate balance between individual patient rights and the wider public good. This theme explores how to reconcile these issues to maximise the benefits offered by harnessing available health data. How can Big Data improve patient outcomes and accelerate clinical development? What are the implications of data ownership, and what will be the role of social media in healthcare?
November 27th, 2014 - Connected Digital Economy Catapult, London
This round table will feature demonstrations of how next-generation technologies and social media will integrate with public health, thus facilitating the burgeoning market for personalised medicines. The session will include disruptive start-ups and technology savvy practitioners finding common ground in the desire to bring stratified medicines to patients.
This event is organised in collaboration with:
December 11th, 2pm - 3:30 PM CET
This webinar updated EFPIA members on Medicines Adaptive Pathways to Patients (MAPPs) and its potential impact on research, development, licensing, HTA, and pricing & reimbursement in relation to early patient access.
Streamed from the European Health Forum Gastein on October 1st, 2014, 9.00 - 11.00 CET
This session brings together industry, policy-makers and international experts on emerging technologies that harness the use of real world data to improve patient outcomes and accelerate clinical development. We will highlight the opportunity provided by robust data analysis and outline the current patient data activities in the EU 28 Member States.
19-20 November, Vilnius:
The main aim of the annual Conference, which will be held under the auspices of the Lithuanian Presidency of the Council of the EU, is to identify the existing best evidence on fostering the development of sustainable health systems throughout the entire Europe.
EFPIA and the Pharmaceutical Research and Manufacturers of America (PhRMA) have issued a joint proposal to enhance responsible clinical trial data sharing. What does this mean practically for research in Europe, and what are the best practices for implementation?